{"classes":[{"categories":[{"measurements":[{"comment":"The upper bound of the 80% CI for median DOR is NA due to insufficient events.","groupId":"OG000","lowerLimit":"2.07","upperLimit":"NA","value":"2.07"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"description":"DOR is measured from the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (or censored at the date of last disease evaluation).","dispersionType":"80% Confidence Interval","groups":[{"description":"Subjects will receive durvalumab and tremelimumab both via intravenous infusion once per day for every 28 day cycles (+ 7 days). Participants will receive tremelimumab for up to 4 cycles (4 doses). Beginning with cycle 5 day 1, subjects will continue to receive durvalumab alone, until clinical or radiological progression.\n\nTremelimumab: Tremelimumab blocks a receptor on immune cells that normally suppresses immune attack.\n\nDurvalumab: Durvalumab is a drug that blocks a protein often produced by cancer cells or surrounding cells to suppress immune cells from attacking cancer cells.","id":"OG000","title":"Tremelimumab + Durvalumab"}],"paramType":"MEDIAN","populationDescription":"This analysis dataset is comprised of all patients who had a CR or PR on treatment.","reportingStatus":"POSTED","timeFrame":"The median of treatment duration is 1.91 months with range (0.00 months - 23.46 months).","title":"Median Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"months"}